| 引用本文: | 李日,付冉,余伟明,温军业,赵世丛,李越昌,张万星.PARP抑制剂在胰腺癌应用中的现状与前景[J].中国现代应用药学,2021,38(13):1659-1664. |
| LI Ri,FU Ran,YU Weiming,WEN Junye,ZHAO Shicong,LI Yuechang,ZHANG Wanxing.Status and Prospect of PARP Inhibitors in Pancreatic Cancer[J].Chin J Mod Appl Pharm(中国现代应用药学),2021,38(13):1659-1664. |
|
| 本文已被：浏览 1260次 下载 963次 |
码上扫一扫！ |
|
|
| PARP抑制剂在胰腺癌应用中的现状与前景 |
|
李日1,2, 付冉3, 余伟明1,2, 温军业2, 赵世丛4, 李越昌4, 张万星2
|
|
1.华北理工大学研究生学院, 河北 唐山 063000;2.河北省人民医院肝胆外科, 石家庄 050000;3.河北医科大学研究生学院, 石家庄 050017;4.河北北方学院研究生学院, 河北 张家口 075000
|
|
| 摘要: |
| 胰腺癌一种是消化道恶性肿瘤，具有进展快、预后差等特点。因为病情的复杂多变，胰腺癌的治疗没有特定有效的治疗方式，因此识别与胰腺癌发生相关的分子机制对于理解胰腺癌的本质及探索新的治疗方式至关重要。BRCA1/2基因是目前已知的与胰腺癌相关的突变基因，BRCA的基因突变会显著增加胰腺癌的患病风险。针对该靶点的PARP抑制剂显示出了较为满意的疗效，PARP抑制剂可通过合成致死、PARP-1-DNA捕获等机制可对BRCA突变的肿瘤产生抑制效果，进而发挥治疗胰腺癌的作用。本文通过对BRCA基因与胰腺癌、PARP抑制剂及其抗肿瘤分子机制、PARP在胰腺癌中的应用的介绍，以期为治疗胰腺癌提供一种新的可靠的治疗方案。 |
| 关键词: 胰腺癌 乳腺癌易感基因 PARP抑制剂 |
| DOI：10.13748/j.cnki.issn1007-7693.2021.13.019 |
| 分类号:R979.1 |
| 基金项目:2019年度河北省医学科学研究重点课题（20190382） |
|
| Status and Prospect of PARP Inhibitors in Pancreatic Cancer |
|
LI Ri1,2, FU Ran3, YU Weiming1,2, WEN Junye2, ZHAO Shicong4, LI Yuechang4, ZHANG Wanxing2
|
|
1.Graduate School of North China University of Science and Technology, Tangshan 063000, China;2.Department of Hepatobiliary Surgery, Hebei Provincial People's Hospital, Shijiazhang 050000, China;3.Graduate School of Hebei Medical University, Shijiazhuang 050017, China;4.Graduate School of Hebei North University, Zhangjiakou 075000, China
|
| Abstract: |
| Pancreatic cancer is a kind of digestive tract malignant tumor, has the characteristics of fast progress and poor prognosis. Because of the complexity of the disease, the treatment of pancreatic cancer is not specific and effective, thereby identifying molecules mechanism that are associated with pancreatic cancer is important to explore new treatments of pancreatic cancer. Mutations in BRCA genes have been linked to the development of pancreatic cancer and can increase the risk of pancreatic cancer. PARP inhibitors which targets the BRCA gene showed a satisfactory curative effect. Through the mechanism of synthetic lethality and PARP-1-DNA capture, PARP inhibitors can produce inhibitory effect on pancreatic cancer which has the mutation of BRCA gene. Through the introduction of the application of BRCA gene, pancreatic cancer PARP inhibitor and its anti-tumor molecular mechanism PARP in pancreatic cancer, this paper aims to provide a new and reliable treatment scheme for pancreatic cancer. |
| Key words: pancreatic cancer breast cancer gene PARP inhibitor |
